Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01270373 | NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?(NeoSAMBA) | unknown | Phase 2 | 112 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 |
| Feb 17, 2020 |
| clinicaltrials |
| NCT04255056 | Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab(PRETTY) | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02690480 | Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer(FLIPPER) | unknown | Phase 2 | 189 | Spanish Breast Cancer Research GroupOTHER | 2 | Feb 5, 2020 | clinicaltrials |
| NCT04246502 | Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03785704 | Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03994107 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Peking Union Medical CollegeOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04236310 | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | unknown | Phase 2 | 37 | Ruijin HospitalOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT01800422 | Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer | unknown | Phase 2 | 50 | Northwestern UniversityOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT04194684 | Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer | unknown | Phase 2 | 108 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT04001725 | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases(OPTIMAL) | unknown | Phase 2 | 110 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04152057 | Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143906 | Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer | unknown | Phase 2 | 200 | Shandong Cancer Hospital and InstituteOTHER | 0 | Oct 30, 2019 | clinicaltrials |
| NCT04094896 | TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer | unknown | Phase 2 | 200 | Guangdong Provincial People's HospitalOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04095390 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer(INPHASE) | unknown | Phase 2 | 60 | Jinming YuOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04088110 | Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer | unknown | Phase 2 | 77 | Fuzhou General HospitalOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03638648 | Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy(RSBNAT) | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 0 | Sep 10, 2019 | clinicaltrials |
| NCT02506777 | Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.(MBC1) | unknown | Phase 2 | 96 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02506790 | Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer | unknown | Phase 2 | 96 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03572361 | Open Label Immunotherapy Trial for Breast Cancer(V3-MOMMO) | unknown | Phase 2 | 20 | Immunitor LLCINDUSTRY | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT04061408 | FSRT in Breast Cancer Patients With Brain Metastases | unknown | Phase 2 | 170 | Fudan UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03024580 | A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer(MEGA) | unknown | Phase 2 | 20 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Aug 15, 2019 | clinicaltrials |
| NCT01907529 | A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer(TENDENCY) | unknown | Phase 2 / Phase 3 | 300 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 9, 2019 | clinicaltrials |
| NCT04034823 | KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer | unknown | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 26, 2019 | clinicaltrials |
| NCT04033172 | Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )(Pyrotinib) | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT04023292 | Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer | unknown | Phase 2 | 185 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT04012918 | Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study(CONCEPT) | unknown | Phase 2 | 124 | Ain Shams UniversityOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT03997539 | A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 256 | Sun Yat-sen UniversityOTHER | 0 | Jun 25, 2019 | clinicaltrials |
| NCT03993964 | Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer | unknown | Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 0 | Jun 21, 2019 | clinicaltrials |
| NCT02768415 | Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01372579 | Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03933982 | A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer(Pyrotinib) | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03959397 | Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer | unknown | Phase 2 | 250 | Jilin UniversityOTHER | 1 | May 22, 2019 | clinicaltrials |
| NCT00499525 | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer | unknown | Phase 2 | 180 | Northwestern UniversityOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | unknown | Phase 2 | 184 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Apr 30, 2019 | clinicaltrials |
| NCT03923166 | Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | unknown | Phase 2 | 35 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03923179 | Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer | unknown | Phase 2 | 32 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03919253 | Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study | unknown | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 0 | Apr 18, 2019 | clinicaltrials |
| NCT03910712 | Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC(Pyrotinib) | unknown | Phase 2 | 250 | Peking Union Medical College HospitalOTHER | 0 | Apr 10, 2019 | clinicaltrials |
| NCT02592746 | A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | unknown | Phase 2 | 182 | Samsung Medical CenterOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03907098 | Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT02580279 | Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy | unknown | Phase 2 | 68 | Shandong Cancer Hospital and InstituteOTHER | 0 | Apr 5, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03876587 | Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC | unknown | Phase 2 | 79 | Zhejiang Cancer HospitalOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT03750396 | Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer(CLEAR) | unknown | Phase 2 | 110 | Gangnam Severance HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03182634 | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial(plasmaMATCH) | unknown | Phase 2 | 1,150 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03518268 | Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor | unknown | Phase 1 / Phase 2 | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Jan 17, 2019 | clinicaltrials |
| NCT02447211 | Topical Doxepin for Radiation-induced Dermatitis | unknown | Phase 2 | 60 | Isfahan University of Medical SciencesOTHER | 1 | Jan 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2020source: clinicaltrials